Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

Case Study: Successful Medical Device Development with EvoLV's Consulting Services

May 28, 2025

Introduction to EvoLV's Consulting Services

In the competitive landscape of medical device development, companies often face numerous challenges, from regulatory hurdles to technical complexities. EvoLV's Consulting Services has carved a niche in this demanding field by providing comprehensive solutions tailored to the unique needs of each client. This case study explores how EvoLV successfully guided a client through the intricate process of developing a cutting-edge medical device.

medical consulting

Understanding Client Needs

Every successful project begins with a deep understanding of the client's specific needs and objectives. EvoLV's initial step involved conducting a thorough assessment of the client's current capabilities and identifying gaps that needed addressing. This comprehensive analysis allowed EvoLV to create a customized strategy that aligned with the client's goals.

By focusing on collaboration and transparency, EvoLV ensured that all stakeholders were on the same page. This approach not only facilitated smoother communication but also fostered an atmosphere of trust and innovation.

Identifying Key Challenges

The client faced several critical challenges, including:

  • Navigating complex regulatory landscapes
  • Integrating advanced technology into the device
  • Ensuring cost-effective production methods
  • Meeting stringent quality standards
medical device development

Strategic Solutions and Implementation

EvoLV's team of experts devised strategic solutions tailored to address each of these challenges effectively. Their approach included:

  1. Leveraging regulatory expertise to streamline approval processes.
  2. Utilizing cutting-edge technology to enhance device functionality.
  3. Implementing innovative manufacturing techniques to reduce costs.
  4. Ensuring rigorous quality control measures to meet industry standards.

This strategic framework not only addressed immediate concerns but also set the foundation for long-term success.

The Role of Technology

Advanced technology played a pivotal role in the successful development of the medical device. EvoLV's team integrated state-of-the-art features that enhanced the usability and effectiveness of the device. By staying at the forefront of technological advancements, EvoLV ensured that the final product was not only competitive but also exceeded market expectations.

technology integration

Results and Impact

The collaboration between EvoLV and the client yielded impressive results. The medical device successfully achieved regulatory approval ahead of schedule, thanks to EvoLV's expertise in navigating complex regulations. This early approval allowed the client to enter the market faster, providing them with a significant competitive advantage.

The incorporation of advanced technologies resulted in a product that was well-received by healthcare professionals and patients alike. This positive reception translated into increased adoption rates and solidified the client's position as an industry leader.

Long-term Benefits

Beyond immediate success, the partnership with EvoLV provided long-term benefits for the client. These included:

  • Enhanced reputation and credibility in the medical device industry
  • Increased market share and revenue growth
  • A robust framework for future product development
business growth

Conclusion

This case study illustrates the transformative impact that EvoLV's Consulting Services can have on medical device development projects. By delivering tailored solutions and leveraging cutting-edge technology, EvoLV empowers clients to overcome challenges, achieve regulatory compliance, and thrive in a competitive market. Their commitment to excellence and innovation sets a benchmark for success in the medical device industry.